Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720377 | 0.89 | P2RY12 (0.73) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL14112845 | 0.86 | P2RY12 (0.70) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL4919919 | 0.85 | P2RY12 (0.79) | P2RY12MEN1 | |
| SCHEMBL5101055 | 0.85 | P2RY12 (0.67) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL4921046 | 0.85 | P2RY12 (0.75) | P2RY12MEN1 | |
| SCHEMBL5267966 | 0.85 | P2RY12 (0.68) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL4719423 | 0.85 | P2RY12 (1.00) | P2RY12MEN1 | |
| SCHEMBL4724486 | 0.85 | P2RY12 (0.69) | P2RY12MEN1 | |
| SCHEMBL5263713 | 0.85 | P2RY12 (0.70) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL5263923 | 0.85 | P2RY12 (0.70) | P2RY12MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | P2RY12 24/4885MEN1 4406/4885ALDH1A1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.